Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations

Daniel M. Moreira, Gerald L. Andriole, J. Curtis Nickel, Claus Roehrborn, Ramiro Castro-Santamaria, Stephen J. Freedland

Research output: Contribution to journalArticle

Abstract

Objectives: To evaluate whether the use of dutasteride is associated with a lower risk of transrectal prostate biopsy-associated urinary tract infection (TPBA-UTI) among men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. Methods: Retrospective analysis of 6045 men undergoing 2-year repeat prostate biopsy in REDUCE. Participants were randomized to receive dutasteride 0.5 mg or placebo daily. TPBA-UTI was defined as the presence of urinary symptoms and the prescription of antibiotics by the treating physician within 30 days after biopsy. Severe TPBA-UTI was defined as TPBA-UTI requiring hospitalization. Comparison of TPBA-UTI between treatment arms was done using Chi-square test and logistic regression adjusting for participant characteristics. Results: Of the subjects included in the study, 3067 (50.7%) were randomized to the placebo arm and 2978 (49.3%) to the dutasteride arm. A total 51 (0.8%) men had TPBA-UTI, including 38 (1.2%) in the placebo arm and 13 (0.4%) in the dutasteride arm (univariable relative risk [RR] = 0.35, P = 0.001; multivariable odds ratio [OR] = 0.34, P = 0.003). The number needed to treat (NNT) to prevent one TPBA-UTI was 125 subjects. Of these, 14 (28%) had severe TPBA-UTI, including 12 (0.4%) in the placebo arm and only 2 (0.07%) in the dutasteride arm (univariable RR = 0.17, P = 0.021; multivariable OR = 0.17, P = 0.031). The NNT to prevent one severe TPBA-UTI was 309 subjects. Conclusion: Among men undergoing a 2-year repeat prostate biopsy, the use of dutasteride for 2 years was associated with a reduced the risk of overall and severe TBPA-UTI. ClinicalTrials.gov Identifier: NCT00056407.

Original languageEnglish (US)
Pages (from-to)1-6
Number of pages6
JournalWorld Journal of Urology
DOIs
StateAccepted/In press - Apr 10 2017

Fingerprint

Urinary Tract Infections
Prostate
Hospitalization
Biopsy
Placebos
Numbers Needed To Treat
Dutasteride
Prostatic Neoplasms
Odds Ratio
Chi-Square Distribution
Prescriptions
Logistic Models
Anti-Bacterial Agents
Physicians

Keywords

  • 5-Alpha-reductase inhibitors
  • Biopsy
  • Double-blind method
  • Dutasteride
  • Humans
  • Male
  • Middle aged
  • Urinary tract infection

ASJC Scopus subject areas

  • Urology

Cite this

Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations. / Moreira, Daniel M.; Andriole, Gerald L.; Nickel, J. Curtis; Roehrborn, Claus; Castro-Santamaria, Ramiro; Freedland, Stephen J.

In: World Journal of Urology, 10.04.2017, p. 1-6.

Research output: Contribution to journalArticle

Moreira, Daniel M. ; Andriole, Gerald L. ; Nickel, J. Curtis ; Roehrborn, Claus ; Castro-Santamaria, Ramiro ; Freedland, Stephen J. / Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations. In: World Journal of Urology. 2017 ; pp. 1-6.
@article{e958a792da034fbe9868fb9703e76bbe,
title = "Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations",
abstract = "Objectives: To evaluate whether the use of dutasteride is associated with a lower risk of transrectal prostate biopsy-associated urinary tract infection (TPBA-UTI) among men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. Methods: Retrospective analysis of 6045 men undergoing 2-year repeat prostate biopsy in REDUCE. Participants were randomized to receive dutasteride 0.5 mg or placebo daily. TPBA-UTI was defined as the presence of urinary symptoms and the prescription of antibiotics by the treating physician within 30 days after biopsy. Severe TPBA-UTI was defined as TPBA-UTI requiring hospitalization. Comparison of TPBA-UTI between treatment arms was done using Chi-square test and logistic regression adjusting for participant characteristics. Results: Of the subjects included in the study, 3067 (50.7{\%}) were randomized to the placebo arm and 2978 (49.3{\%}) to the dutasteride arm. A total 51 (0.8{\%}) men had TPBA-UTI, including 38 (1.2{\%}) in the placebo arm and 13 (0.4{\%}) in the dutasteride arm (univariable relative risk [RR] = 0.35, P = 0.001; multivariable odds ratio [OR] = 0.34, P = 0.003). The number needed to treat (NNT) to prevent one TPBA-UTI was 125 subjects. Of these, 14 (28{\%}) had severe TPBA-UTI, including 12 (0.4{\%}) in the placebo arm and only 2 (0.07{\%}) in the dutasteride arm (univariable RR = 0.17, P = 0.021; multivariable OR = 0.17, P = 0.031). The NNT to prevent one severe TPBA-UTI was 309 subjects. Conclusion: Among men undergoing a 2-year repeat prostate biopsy, the use of dutasteride for 2 years was associated with a reduced the risk of overall and severe TBPA-UTI. ClinicalTrials.gov Identifier: NCT00056407.",
keywords = "5-Alpha-reductase inhibitors, Biopsy, Double-blind method, Dutasteride, Humans, Male, Middle aged, Urinary tract infection",
author = "Moreira, {Daniel M.} and Andriole, {Gerald L.} and Nickel, {J. Curtis} and Claus Roehrborn and Ramiro Castro-Santamaria and Freedland, {Stephen J.}",
year = "2017",
month = "4",
day = "10",
doi = "10.1007/s00345-017-2036-2",
language = "English (US)",
pages = "1--6",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Dutasteride is associated with reduced risk of transrectal prostate biopsy-associated urinary tract infection and related hospitalizations

AU - Moreira, Daniel M.

AU - Andriole, Gerald L.

AU - Nickel, J. Curtis

AU - Roehrborn, Claus

AU - Castro-Santamaria, Ramiro

AU - Freedland, Stephen J.

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Objectives: To evaluate whether the use of dutasteride is associated with a lower risk of transrectal prostate biopsy-associated urinary tract infection (TPBA-UTI) among men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. Methods: Retrospective analysis of 6045 men undergoing 2-year repeat prostate biopsy in REDUCE. Participants were randomized to receive dutasteride 0.5 mg or placebo daily. TPBA-UTI was defined as the presence of urinary symptoms and the prescription of antibiotics by the treating physician within 30 days after biopsy. Severe TPBA-UTI was defined as TPBA-UTI requiring hospitalization. Comparison of TPBA-UTI between treatment arms was done using Chi-square test and logistic regression adjusting for participant characteristics. Results: Of the subjects included in the study, 3067 (50.7%) were randomized to the placebo arm and 2978 (49.3%) to the dutasteride arm. A total 51 (0.8%) men had TPBA-UTI, including 38 (1.2%) in the placebo arm and 13 (0.4%) in the dutasteride arm (univariable relative risk [RR] = 0.35, P = 0.001; multivariable odds ratio [OR] = 0.34, P = 0.003). The number needed to treat (NNT) to prevent one TPBA-UTI was 125 subjects. Of these, 14 (28%) had severe TPBA-UTI, including 12 (0.4%) in the placebo arm and only 2 (0.07%) in the dutasteride arm (univariable RR = 0.17, P = 0.021; multivariable OR = 0.17, P = 0.031). The NNT to prevent one severe TPBA-UTI was 309 subjects. Conclusion: Among men undergoing a 2-year repeat prostate biopsy, the use of dutasteride for 2 years was associated with a reduced the risk of overall and severe TBPA-UTI. ClinicalTrials.gov Identifier: NCT00056407.

AB - Objectives: To evaluate whether the use of dutasteride is associated with a lower risk of transrectal prostate biopsy-associated urinary tract infection (TPBA-UTI) among men in the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. Methods: Retrospective analysis of 6045 men undergoing 2-year repeat prostate biopsy in REDUCE. Participants were randomized to receive dutasteride 0.5 mg or placebo daily. TPBA-UTI was defined as the presence of urinary symptoms and the prescription of antibiotics by the treating physician within 30 days after biopsy. Severe TPBA-UTI was defined as TPBA-UTI requiring hospitalization. Comparison of TPBA-UTI between treatment arms was done using Chi-square test and logistic regression adjusting for participant characteristics. Results: Of the subjects included in the study, 3067 (50.7%) were randomized to the placebo arm and 2978 (49.3%) to the dutasteride arm. A total 51 (0.8%) men had TPBA-UTI, including 38 (1.2%) in the placebo arm and 13 (0.4%) in the dutasteride arm (univariable relative risk [RR] = 0.35, P = 0.001; multivariable odds ratio [OR] = 0.34, P = 0.003). The number needed to treat (NNT) to prevent one TPBA-UTI was 125 subjects. Of these, 14 (28%) had severe TPBA-UTI, including 12 (0.4%) in the placebo arm and only 2 (0.07%) in the dutasteride arm (univariable RR = 0.17, P = 0.021; multivariable OR = 0.17, P = 0.031). The NNT to prevent one severe TPBA-UTI was 309 subjects. Conclusion: Among men undergoing a 2-year repeat prostate biopsy, the use of dutasteride for 2 years was associated with a reduced the risk of overall and severe TBPA-UTI. ClinicalTrials.gov Identifier: NCT00056407.

KW - 5-Alpha-reductase inhibitors

KW - Biopsy

KW - Double-blind method

KW - Dutasteride

KW - Humans

KW - Male

KW - Middle aged

KW - Urinary tract infection

UR - http://www.scopus.com/inward/record.url?scp=85017266676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017266676&partnerID=8YFLogxK

U2 - 10.1007/s00345-017-2036-2

DO - 10.1007/s00345-017-2036-2

M3 - Article

SP - 1

EP - 6

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

ER -